Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

A key anti-viral protein, RSAD2/VIPERIN, restricts the release of measles virus from infected cells.

Kurokawa C, Iankov ID, Galanis E.

Virus Res. 2019 Apr 2;263:145-150. doi: 10.1016/j.virusres.2019.01.014. Epub 2019 Jan 23.

PMID:
30684519
2.

Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.

Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, Maurer MJ, Oberg AL, Schroeder MA, Giannini C, Greiner SM, Becker MA, Thompson EA, Haluska P, Jentoft ME, Parney IF, Weroha SJ, Jen J, Sarkaria JN, Galanis E.

J Natl Cancer Inst. 2018 Oct 1;110(10):1123-1132. doi: 10.1093/jnci/djy033.

3.

Chronic Phenotype Characterization of a Large-Animal Model of Hereditary Tyrosinemia Type 1.

Elgilani F, Mao SA, Glorioso JM, Yin M, Iankov ID, Singh A, Amiot B, Rinaldo P, Marler RJ, Ehman RL, Grompe M, Lillegard JB, Hickey RD, Nyberg SL.

Am J Pathol. 2017 Jan;187(1):33-41. doi: 10.1016/j.ajpath.2016.09.013. Epub 2016 Nov 14.

4.

Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy.

Iankov ID, Kurokawa CB, D'Assoro AB, Ingle JN, Domingo-Musibay E, Allen C, Crosby CM, Nair AA, Liu MC, Aderca I, Federspiel MJ, Galanis E.

Cancer Gene Ther. 2015 Sep;22(9):438-44. doi: 10.1038/cgt.2015.36. Epub 2015 Aug 14.

5.

Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens.

Iankov ID, Federspiel MJ, Galanis E.

Vaccine. 2013 Oct 1;31(42):4795-801. doi: 10.1016/j.vaccine.2013.07.085. Epub 2013 Aug 12.

6.

Neutralization capacity of measles virus H protein specific IgG determines the balance between antibody-enhanced infectivity and protection in microglial cells.

Iankov ID, Penheiter AR, Griesmann GE, Carlson SK, Federspiel MJ, Galanis E.

Virus Res. 2013 Mar;172(1-2):15-23. doi: 10.1016/j.virusres.2012.12.002. Epub 2012 Dec 21.

7.

Development of monoclonal antibody-based immunoassays for detection of Helicobacter pylori neutrophil-activating protein.

Iankov ID, Penheiter AR, Carlson SK, Galanis E.

J Immunol Methods. 2012 Oct 31;384(1-2):1-9. doi: 10.1016/j.jim.2012.06.010. Epub 2012 Jun 28.

8.

Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.

Iankov ID, Allen C, Federspiel MJ, Myers RM, Peng KW, Ingle JN, Russell SJ, Galanis E.

Mol Ther. 2012 Jun;20(6):1139-47. doi: 10.1038/mt.2012.4. Epub 2012 Feb 14.

9.

Oncolytic measles virus retargeting by ligand display.

Msaouel P, Iankov ID, Allen C, Russell SJ, Galanis E.

Methods Mol Biol. 2012;797:141-62. doi: 10.1007/978-1-61779-340-0_11.

10.

Attenuated oncolytic measles virus strains as cancer therapeutics.

Msaouel P, Iankov ID, Dispenzieri A, Galanis E.

Curr Pharm Biotechnol. 2012 Jul;13(9):1732-41. Review.

11.

Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein.

Iankov ID, Haralambieva IH, Galanis E.

Vaccine. 2011 Feb 11;29(8):1710-20. doi: 10.1016/j.vaccine.2010.12.020. Epub 2010 Dec 21.

12.

Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model.

Iankov ID, Msaouel P, Allen C, Federspiel MJ, Bulur PA, Dietz AB, Gastineau D, Ikeda Y, Ingle JN, Russell SJ, Galanis E.

Breast Cancer Res Treat. 2010 Aug;122(3):745-54. doi: 10.1007/s10549-009-0602-z. Epub 2009 Nov 6.

13.

Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.

Msaouel P, Iankov ID, Allen C, Aderca I, Federspiel MJ, Tindall DJ, Morris JC, Koutsilieris M, Russell SJ, Galanis E.

Mol Ther. 2009 Dec;17(12):2041-8. doi: 10.1038/mt.2009.218. Epub 2009 Sep 22.

14.

Converting tumor-specific markers into reporters of oncolytic virus infection.

Iankov ID, Hillestad ML, Dietz AB, Russell SJ, Galanis E.

Mol Ther. 2009 Aug;17(8):1395-403. doi: 10.1038/mt.2009.92. Epub 2009 May 26.

15.

Engineered measles virus as a novel oncolytic therapy against prostate cancer.

Msaouel P, Iankov ID, Allen C, Morris JC, von Messling V, Cattaneo R, Koutsilieris M, Russell SJ, Galanis E.

Prostate. 2009 Jan 1;69(1):82-91. doi: 10.1002/pros.20857.

16.

Oncolytic measles virus strains in the treatment of gliomas.

Allen C, Paraskevakou G, Liu C, Iankov ID, Msaouel P, Zollman P, Myers R, Peng KW, Russell SJ, Galanis E.

Expert Opin Biol Ther. 2008 Feb;8(2):213-20. doi: 10.1517/14712598.8.2.213 . Review. Erratum in: Expert Opin Biol Ther. 2008 Jun;8(6):855. Myers, Rae [added]; Peng, Kah Whye [added]; Russell, Stephen J [added].

17.

Bactericidal monoclonal antibody against Moraxella catarrhalis lipooligosaccharide cross-reacts with Haemophilus Spp.

Gergova RT, Iankov ID, Haralambieva IH, Mitov IG.

Curr Microbiol. 2007 Feb;54(2):85-90. Epub 2007 Jan 5.

PMID:
17211546
18.

Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.

Iankov ID, Blechacz B, Liu C, Schmeckpeper JD, Tarara JE, Federspiel MJ, Caplice N, Russell SJ.

Mol Ther. 2007 Jan;15(1):114-22.

19.

Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response.

Iankov ID, Pandey M, Harvey M, Griesmann GE, Federspiel MJ, Russell SJ.

J Virol. 2006 Sep;80(17):8530-40.

20.

Chlamydophila pneumoniae induces p44/p42 mitogen-activated protein kinase activation in human fibroblasts through Toll-like receptor 4.

Haralambieva IH, Iankov ID, Ivanova PV, Mitev V, Mitov IG.

J Med Microbiol. 2004 Dec;53(Pt 12):1187-93.

PMID:
15585496
21.

Protective efficacy of IgA monoclonal antibodies to O and H antigens in a mouse model of intranasal challenge with Salmonella enterica serotype Enteritidis.

Iankov ID, Petrov DP, Mladenov IV, Haralambieva IH, Kalev OK, Balabanova MS, Mitov IG.

Microbes Infect. 2004 Aug;6(10):901-10.

PMID:
15310466
22.

Production and characterization of monoclonal immunoglobulin A antibodies directed against Salmonella H:g,m flagellar antigen.

Iankov ID, Petrov DP, Mladenov IV, Haralambieva IH, Ivanova R, R Velev V, Mitov IG.

FEMS Immunol Med Microbiol. 2002 Jun 3;33(2):107-13.

23.
24.

Characterisation of 20-kDa lectin-spermagglutinin from Arum maculatum that prevents Chlamydia pneumoniae infection of L-929 fibroblast cells.

Mladenov IV, Haralambieva IH, Iankov ID, Mitov IG.

FEMS Immunol Med Microbiol. 2002 Feb 18;32(3):249-54.

26.

Monoclonal antibodies of IgA isotype specific for lipopolysaccharide of Salmonella enteritidis: production, purification, characterization and application as serotyping reagents.

Iankov ID, Petrov DP, Mladenov IV, Haralambieva IH, Ivanova R, Sechanova L, Mitov IG.

FEMS Microbiol Lett. 2001 Mar 15;196(2):215-21.

Supplemental Content

Loading ...
Support Center